- Report
- April 2025
- 361 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 367 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 286 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 384 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 372 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 66 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 378 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 235 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 74 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 66 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 72 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- March 2025
- 150 Pages
Global
From €4414EUR$4,850USD£3,749GBP
- Report
- April 2025
- 372 Pages
Global
From €5324EUR$5,850USD£4,522GBP
- Report
- April 2025
- 400 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- April 2025
- 250 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- April 2025
- 250 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- April 2025
- 250 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- April 2025
- 250 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- April 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP
- Report
- April 2025
- 200 Pages
Global
From €4087EUR$4,490USD£3,471GBP

Macular Degeneration is a condition that affects the central part of the retina, known as the macula, which is responsible for sharp, central vision. It is the leading cause of vision loss in people over the age of 50. Optical treatments for Macular Degeneration include laser photocoagulation, photodynamic therapy, and anti-VEGF injections. Laser photocoagulation is used to reduce the risk of further vision loss by sealing off leaking blood vessels in the macula. Photodynamic therapy is used to reduce the growth of abnormal blood vessels in the macula. Anti-VEGF injections are used to reduce the growth of abnormal blood vessels and improve vision.
Companies in the Macular Degeneration market include Novartis, Regeneron, Allergan, Genentech, and Roche. Show Less Read more